News - Research, Oncology

Filter

Current filters:

ResearchOncology

Popular Filters

1 to 25 of 589 results

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer

25-07-2014

German drug major Bayer and Onyx Pharmaceuticals, an Amgen subsidiary (Nasdaq: AMGN), have said that…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

23-07-2014

US development-stage company Puma Biotechnology saw its share more than triple to $190 in after-hours…

BiotechnologyLicensingneratinibOncologyPB272PfizerPuma BiotechResearchTrastuzumabUSA

Zeltia diversifying its business pharma model to finance R&D pipeline

22-07-2014

PharmaMar, biopharmaceutical company which represents the main affiliate of Spanish Grupo Zeltia is diversifying…

AplidinBiotechnologyChugai PharmaceuticalGP PharmLicensingOncologyPharmaMarPM 1183PolitrateResearchZeltia

AstraZeneca's MedImmune announces cancer immunotherapies partnership with Advaxis

AstraZeneca's MedImmune announces cancer immunotherapies partnership with Advaxis

22-07-2014

Anglo-Swedish drug major AstraZeneca says that its global biologics research and development arm MedImmune…

AdvaxisADXS-HPVAstraZenecaBiotechnologyMedImmuneOncologyPapillomavirusResearchSweden

Regeneus's human cancer vaccine pipeline adds almost $4 million to valuation

Regeneus's human cancer vaccine pipeline adds almost $4 million to valuation

22-07-2014

Australian biotech company Regeneus has expanded its portfolio to include licensing of global rights…

AustraliaBiotechnologyFinancialOncologyOsteosarcomaRegeneusResearchSarcoma

Queen's University Belfast researchers' breakthrough leads to new clinical trial in bowel cancer

Queen's University Belfast researchers' breakthrough leads to new clinical trial in bowel cancer

21-07-2014

Cancer Research UK scientists have discovered how two genes – called MEK and MET – cause bowel cancer…

Colorectal cancerOncologyPharmaceuticalResearchUKUniversity Belfast

Trametinib and dabrafenib gives overall survival benefit compared to vemurafenib

Trametinib and dabrafenib gives overall survival benefit compared to vemurafenib

17-07-2014

GlaxoSmithKline says that the Independent Data Monitoring Committee (IDMC) has recommended a Phase III…

BRAFdabrafenibGlobalGSKMetastatic cutaneous melanomaOncologyPharmaceuticalResearchtrametinibvemurafenib

Final funding boost for immatics to complete Phase III study

Final funding boost for immatics to complete Phase III study

16-07-2014

Germany’s privately-held immatics biotechnologies GmbH has received 22 million euros ($29 million)…

BiotechnologyFinancialGermanyimmatics biotechnologiesOncologyRenal cell carcinomaResearchSutent

Hemispherx links with SA biotech Bioclones on cancer vaccine

Hemispherx links with SA biotech Bioclones on cancer vaccine

14-07-2014

USA-based Hemispherx Biopharma has entered a strategic alliance to develop multiple projects with Bioclones,…

AlferonAmpligenBioclonesBiotechnologyHemispherx BioPharmaOncologyResearchSouth AfricaVaccines

Bayer milestone for Compugen in cancer immunotherapy deal

Bayer milestone for Compugen in cancer immunotherapy deal

07-07-2014

Shares of Israel-based Compugen rose nearly 4% in pre-market trading today, after it said it has achieved…

BayerCompugenFinancialOncologyPharmaceuticalResearch

Erbitux equal to Avastin in colorectal cancer survival, FIRE-3 study shows

Erbitux equal to Avastin in colorectal cancer survival, FIRE-3 study shows

30-06-2014

Merck Serono, the biotech subsidiary of Germany’s Merck KGaA, has released positive new clinical trial…

AvastinBiotechnologyErbituxMerck KGaAMerck SeronoOncologyResearchRoche

Positive data on Merck & Co’s nausea drug Emend Ph III trial in children

Positive data on Merck & Co’s nausea drug Emend Ph III trial in children

30-06-2014

Positive results have been announced by US pharma giant Merck & Co from a global, investigational Phase…

EmendMerck & CoOncologyPharmaceuticalRegulationResearch

Bristol-Myers Ph III nivolumab trial stopped early on good results

Bristol-Myers Ph III nivolumab trial stopped early on good results

25-06-2014

Shares of US pharma major Bristol-Myers Squibb rose 2.6% to $49.55 in post-market trading on June 25,…

Bristol-Myers SquibbnivolumabOncologyPharmaceuticalResearch

Mersana and Merck KGaA to develop next-gen antibody-drug conjugates

Mersana and Merck KGaA to develop next-gen antibody-drug conjugates

24-06-2014

Privately-held US biotech company Mersana Therapeutics and EMD Serono, the North America biopharmaceutical…

BiotechnologyEMD SeronoMerck KGaAOncologyResearch

Takeda halts development of orteronel for prostate cancer

Takeda halts development of orteronel for prostate cancer

19-06-2014

Japan’s largest drugmaker Takeda Pharmaceutical says that it has voluntarily decided to end the development…

OncologyorteronelPharmaceuticalResearchTakeda Pharmaceutical

Celgene exercises option for Agios Pharma’s AG-221

Celgene exercises option for Agios Pharma’s AG-221

17-06-2014

Metabolism specialist Agios Pharmaceuticals says that its partner, biotech major Celgene Corp, has exercised…

AG-221Agios PharmaceuticalsBiotechnologyCelgeneLicensingOncologyRegulationResearchUSA

Doomed future for Tykerb in breast cancer arena, says analyst

Doomed future for Tykerb in breast cancer arena, says analyst

16-06-2014

The future of Tykerb (lapatinib) in the breast cancer market looks bleak, after the combination of GlaxoSmithKline’s…

BiotechnologyGlaxoSmithKlineMarkets & MarketingNovartisOncologyResearchTykerb

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market

13-06-2014

Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

GSK’s eltrombopag performs well in Phase III PETIT2 study

GSK’s eltrombopag performs well in Phase III PETIT2 study

13-06-2014

UK pharma major GlaxoSmithKline has announced positive results from the Phase III PETIT2 study evaluating…

eltrombopagGlaxoSmithKlineOncologyPharmaceuticalResearchThrombocytopenic purpuraUK

1 to 25 of 589 results

Back to top